Leading Companies

Key players operating in the market are focusing on facility expansion in order to increase their geographical presence in the global market. In January 2020, Celltrion Group, a biopharmaceutical company plans to build biopharmaceutical plant in China. The new plant is focusing on to carry out large scale contract manufacturing organization for the Chinese market with a plant capacity of 120,000 liters, which will be the largest biopharmaceutical plant in the China.

Moreover, increasing adoption of inorganic growth strategies such as merger and acquisition by key players operating in the market is expected to drive market growth over the forecast period. In January 2020, Cognate BioServices, a contract development and manufacturing organization (CDMO) specialized in cell and cell-mediated gene therapy products has acquired the Cobra Biologics, a CDMO specialized in providing development and manufacturing services for plasmid DNA and viral vector. With this acquisition Cognate BioServices deliver drug development and manufacturing solutions to the cell and gene immunotherapy and regenerative medicine industry around the world.

In August 2019, Patheon merged with Royal DSM to form private company DPx, a Contract Manufacturing Organization (CMO). The new company comprises of three businesses - fine chemicals and API production, pharmaceutical services including contract manufacturing and proprietary products and technologies falling under the banner of life sciences acquired by Patheon in October 2012.

Furthermore, key players operating in the market are focusing on strategic partnership for expanding its contract manufacturing facility. For instance in January 2020, Indapta Therapeutics and Lonza, a biopharmaceutical company announced a strategic partnership to advance a next-generation, off-the-shelf, allogeneic immuno-oncology therapy. Under the terms of this partnership, Lonza will manufacture Indapta’s off-the-shelf, allogeneic G-NK cell therapy under current good manufacturing practices (cGMP) for use in clinical studies. Similarly, Indapta will leverage Lonza’s process development capabilities and expertise to ensure a robust, reproducible and scalable cGMP process. Process development and manufacturing will take place in Lonza's state-of-the-art cell and gene therapy manufacturing facility in Houston (TX), USA.

The key players in operating in the global biopharmaceutical contract manufacturing market include Lonza Group Ltd., ProBioGen AG, Boehringher Ingelheim, BIOMEVA GmbH, Celonic GmbH, Sandoz, Fujifilm Diosynth Biotechnology, and Rentschler Biotechnologie.